Posted September 3, 2020
As we anticipate the arrival of a fast-tracked and liability-free SARS-Cov-2 vaccine candidate, vaccine proponents and developers like Paul Offit and Peter Hotez have been notably reticent. It would be wise to consider why. Both doctors have acknowledged previous failures in attempted coronavirus vaccines and have alluded to the issue of “antibody-dependent enhancement,” also called “pathogenic priming.” Read more.